Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times.
The cytotoxic part may comprise of any molecule which has the capability to induce cell death either by interfering with the cell machinery, modifying cell membrane, or by induction of apoptotic pathways. The cytotoxicity thus successfully delivered either to cytoplasm or the ribosomes of the target cell may be lethal to the cell.
During its ignition era, immunotoxins basically comprised of monoclonal antibodies (MAb) or growth factors chemically conjugated to protein toxins by the formation of the disulphide bonds. These molecules contained full length protein toxins are were not that cell specific. With progress in the research and technology, second generation immunotoxins made an entry. They were modulated in a way to remove the toxin mediated cell binding and spare the normal cells from cytotoxicity. The immunotoxins of this generation contained full length Immunoglobulin (IgG) bound to the toxic moiety.
The entry of third generation was marked by coming of recombinant technology which was targeted to remove the immunogenicity by shifting from murine origin immunoglobulins to humanized recombinant IgGs. The molecules of this generation thus formed consisted of fragments of variable domain (Fv) conjugated to IgG. Thus, created immunotoxins had excellent activity, specificity, better penetration and less immunogenicity.
Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report Highlights:
- Introduction to Immunotoxins
- Cancer Immunotoxins Therapy Analysis
- Advantages of Immunotoxins upon other Anticancerous Drugs
- Applications of Immunotoxins to Multiple Cancer Therapies
- Global Cancer Immunotoxins Market Future Prospects
- Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
- Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
- Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs
- AREVA Med
- Bayer HealthCare
- Celldex Therapeutics
- CuraGen Corporation
- Heidelberg Pharma
- Neurocrine Biosciences
- Research Corporation Technologies
- Seattle Genetics
- Sorrento Therapeutics
For more information visit http://www.researchandmarkets.com/research/zpgq83/global_cancer
Sector: Oncology Drugs
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunotoxins-market--clinical-pipeline-insight-report-2020---research-and-markets-300312861.html
SOURCE Research and Markets